Cara Therapeutics logo

Cara Therapeutics share price today

(CARA)

Cara Therapeutics share price is $5.36 & ₹459.94 as on 7 Jan 2025, 2.30 'hrs' IST

$5.36

0.14

(2.68%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Cara Therapeutics share price in Dollar and Rupees. Guide to invest in Cara Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Cara Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Cara Therapeutics share price movements

  • Today's Low: $5.05
    Today's High: $5.52

    Day's Volatility :8.57%

  • 52 Weeks Low: $2.71
    52 Weeks High: $13.80

    52 Weeks Volatility :80.37%

Cara Therapeutics Returns

PeriodCara Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
69.86%
-8.4%
0.0%
6 Months
52.42%
-3.8%
0.0%
1 Year
-35.95%
-0.1%
0.0%
3 Years
-96.41%
2.9%
-19.8%

Cara Therapeutics Key Statistics

in dollars & INR

Previous Close
$5.22
Open
$5.1
Today's High
$5.5232
Today's Low
$5.05
Market Capitalization
$28.0M
Today's Volume
$92.5K
52 Week High
$13.8
52 Week Low
$2.7084
Revenue TTM
$11.0M
EBITDA
$-104.7M
Earnings Per Share (EPS)
$-21.0
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-184.32%

How to invest in Cara Therapeutics from India?

It is very easy for Indian residents to invest directly in Cara Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cara Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cara Therapeutics or CARA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cara Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cara Therapeutics shares which would translate to 0.160 fractional shares of Cara Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cara Therapeutics, in just a few clicks!

Returns in Cara Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Cara Therapeutics investment value today

Current value as on today

₹68,989

Returns

₹31,011

(-31.01%)

Returns from Cara Therapeutics Stock

₹34,233 (-34.23%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Cara Therapeutics

141%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Cara Therapeutics on INDmoney from India has grown in the last 30 days as on Jan 7, 2025. 141% more investors are searching Cara Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Cara Therapeutics

  • Vanguard Group Inc

    4.10%

  • Chescapmanager LLC

    3.10%

  • Farallon Capital Management, L.L.C.

    2.84%

  • Disciplined Growth Investors Inc

    2.03%

  • Renaissance Technologies Corp

    2.02%

  • Two Sigma Advisers, LLC

    1.58%

Analyst Recommendation on Cara Therapeutics

Buy

    81%Buy

    18%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for Cara Therapeutics(by analysts ranked 0 to 5 stars)

Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
10
11
Hold
2
2
2
Sell
0
0
0

Analyst Forecast on Cara Therapeutics

What analysts predicted

Upside of 126.12%

Current:

$5.36

Target:

$12.12

Insights on Cara Therapeutics

  • Price Movement

    In the last 7 days, CARA stock has moved up by 22.5%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 991.0K → 2.55M (in $), with an average increase of 61.2% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -32.33M → -12.47M (in $), with an average increase of 39.7% per quarter
  • CARA vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 23.7% return, outperforming this stock by 52.8%
  • CARA vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 55.2% return, outperforming this stock by 151.5%
  • Price to Sales

    ForCARA every $1 of sales, investors are willing to pay $25.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Cara Therapeutics Financials in INR & Dollars

FY18Y/Y Change
Revenue
$13.5M
↑ 1378.49%
Net Income
$-74.0M
↑ 27.33%
Net Profit Margin
-549.51%
↑ 5830.84%
FY19Y/Y Change
Revenue
$19.9M
↑ 47.64%
Net Income
$-106.4M
↑ 43.72%
Net Profit Margin
-534.91%
↑ 14.6%
FY20Y/Y Change
Revenue
$135.1M
↑ 579.28%
Net Income
$8.4M
↓ 107.91%
Net Profit Margin
6.23%
↑ 541.14%
FY21Y/Y Change
Revenue
$23.0M
↓ 82.95%
Net Income
$-88.2M
↓ 1148.67%
Net Profit Margin
-382.98%
↓ 389.21%
FY22Y/Y Change
Revenue
$41.9M
↑ 81.81%
Net Income
$-83.4M
↓ 5.42%
Net Profit Margin
-199.23%
↑ 183.75%
FY23Y/Y Change
Revenue
$21.0M
↓ 49.92%
Net Income
$-118.5M
↑ 42.08%
Net Profit Margin
-565.21%
↓ 365.98%
Q2 FY23Q/Q Change
Revenue
$6.9M
↑ 12.46%
Net Income
$-31.5M
↑ 22.58%
Net Profit Margin
-454.05%
↓ 37.5%
Q3 FY23Q/Q Change
Revenue
$4.9M
↓ 29.81%
Net Income
$-28.0M
↓ 10.95%
Net Profit Margin
-576.08%
↓ 122.03%
Q4 FY23Q/Q Change
Revenue
$3.0M
↓ 38.27%
Net Income
$-32.3M
↑ 15.36%
Net Profit Margin
-1.1K%
↓ 500.38%
Q1 FY24Q/Q Change
Revenue
$2.1M
↓ 28.93%
Net Income
$-30.7M
↓ 5.07%
Net Profit Margin
-1.4K%
↓ 361.29%
Q2 FY24Q/Q Change
Revenue
$991.0K
↓ 53.58%
Net Income
$-20.0M
↓ 34.79%
Net Profit Margin
-2.0K%
↓ 582.03%
Q3 FY24Q/Q Change
Revenue
$2.6M
↑ 157.92%
Net Income
$-12.5M
↓ 37.67%
Net Profit Margin
-488.11%
↑ 1531.67%
FY18Y/Y Change
Profit
$13.5M
↑ 1378.49%
FY19Y/Y Change
Profit
$19.9M
↑ 47.64%
FY20Y/Y Change
Profit
$28.0M
↑ 40.86%
FY21Y/Y Change
Profit
$23.0M
↓ 17.79%
FY22Y/Y Change
Profit
$34.6M
↑ 50.26%
FY23Y/Y Change
Profit
$14.8M
↓ 57.24%
Q2 FY23Q/Q Change
Profit
$5.5M
↑ 54.27%
Q3 FY23Q/Q Change
Profit
$3.3M
↓ 40.02%
Q4 FY23Q/Q Change
Profit
$2.3M
↓ 30.05%
Q1 FY24Q/Q Change
Profit
$1.5M
↓ 36.34%
Q2 FY24Q/Q Change
Profit
$991.0K
↓ 32.72%
Q3 FY24Q/Q Change
Profit
$2.6M
↑ 157.92%
FY18Y/Y Change
Operating Cash Flow
$-22.3M
↓ 59.32%
Investing Cash Flow
$-82.8M
↑ 131.34%
Financing Cash Flow
$110.8M
↑ 26.03%
FY19Y/Y Change
Operating Cash Flow
$-109.2M
↑ 389.78%
Investing Cash Flow
$-30.5M
↓ 63.15%
Financing Cash Flow
$142.6M
↑ 28.69%
FY20Y/Y Change
Operating Cash Flow
$-5.5M
↓ 94.98%
Investing Cash Flow
$-20.3M
↓ 33.56%
Financing Cash Flow
$39.1M
↓ 72.55%
FY21Y/Y Change
Operating Cash Flow
$-60.1M
↑ 995.08%
Investing Cash Flow
$-4.8M
↓ 76.57%
Financing Cash Flow
$46.6M
↑ 19.08%
FY22Y/Y Change
Operating Cash Flow
$-78.7M
↑ 31.03%
Investing Cash Flow
$128.7M
↓ 2809.05%
Financing Cash Flow
$311.0K
↓ 99.33%
Q2 FY23Q/Q Change
Operating Cash Flow
$-20.4M
↓ 40.94%
Investing Cash Flow
$32.8M
↑ 85.24%
Financing Cash Flow
$1.1M
↑ 99.29%
Q3 FY23Q/Q Change
Operating Cash Flow
$-19.6M
↓ 3.91%
Investing Cash Flow
$23.2M
↓ 29.41%
Financing Cash Flow
$1.1M
↑ 0.0%

Cara Therapeutics Technicals Summary

Sell

Neutral

Buy

Cara Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Cara Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cara Therapeutics Inc
48.97%
52.42%
-35.95%
-96.41%
-97.17%
Regeneron Pharmaceuticals, Inc.
-8.86%
-31.87%
-20.46%
15.59%
87.28%
Biontech Se
-4.16%
43.82%
3.49%
-49.66%
167.6%
Alnylam Pharmaceuticals, Inc.
-8.45%
-8.03%
19.03%
56.02%
98.44%
Vertex Pharmaceuticals Incorporated
-14.11%
-16.23%
-2.87%
81.78%
76.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cara Therapeutics Inc
NA
NA
0.0
0.0
-1.84
-0.63
NA
1.05
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cara Therapeutics Inc
Buy
$28.0M
-97.17%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
87.28%
17.61
33.61%
Biontech Se
Buy
$27.3B
167.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
98.44%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
76.8%
32.84
-4.51%

About Cara Therapeutics

cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Organization
Cara Therapeutics
Employees
55
CEO
Mr. Christopher A. Posner
Industry
Health Technology

Management People of Cara Therapeutics

NameTitle
Mr. Christopher A. Posner
President, CEO & Director
Mr. Ryan D. Maynard
Chief Financial Officer
Dr. Derek T. Chalmers D.Sc., Ph.D.
Co-Founder & Senior Advisor
Mr. Matthew Murphy
Manager of Investor Relations

Important FAQs about investing in Cara Therapeutics from India :

What is Cara Therapeutics share price today?

Cara Therapeutics share price today stands at $5.36, Open: $5.10 ; Previous Close: $5.22 ; High: $5.52 ; Low: $5.05 ; 52 Week High: $13.80 ; 52 Week Low: $2.71. The stock opens at $5.10, after a previous close of $5.22. The stock reached a daily high of $5.52 and a low of $5.05, with a 52-week high of $13.80 and a 52-week low of $2.71.

Can Indians buy Cara Therapeutics shares?

Yes, Indians can invest in the Cara Therapeutics (CARA) from India.

With INDmoney, you can buy Cara Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Cara Therapeutics at zero transaction cost.

How can I buy Cara Therapeutics shares from India?

It is very easy to buy Cara Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cara Therapeutics be purchased?

Yes, you can buy fractional shares of Cara Therapeutics with INDmoney app.

What are the documents required to start investing in Cara Therapeutics stocks?

To start investing in Cara Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Cara Therapeutics

Today’s highest price of Cara Therapeutics (CARA) is $5.52.

Today’s lowest price of Cara Therapeutics (CARA) is $5.05.

What is today's market capitalisation of Cara Therapeutics

Today's market capitalisation of Cara Therapeutics CARA is 28.0M

What is the 52 Week High and Low Range of Cara Therapeutics

  • 52 Week High

    $13.80

  • 52 Week Low

    $2.71

What are the historical returns of Cara Therapeutics?

  • 1 Month Returns

    48.97%

  • 3 Months Returns

    52.42%

  • 1 Year Returns

    -35.95%

  • 5 Years Returns

    -97.17%

Who is the Chief Executive Officer (CEO) of Cara Therapeutics

Mr. Christopher A. Posner is the current Chief Executive Officer (CEO) of Cara Therapeutics.